Valuation: Catalyst Pharmaceuticals, Inc.

Market Cap 3.85B 3.34B 3.11B 2.86B 5.4B 367B 5.46B 36.56B 14.33B 183B 14.48B 14.16B 608B P/E 2024
15.9x
P/E 2025 13.9x
Enterprise Value 3.15B 2.73B 2.54B 2.34B 4.41B 299B 4.46B 29.86B 11.7B 150B 11.82B 11.56B 496B EV / Sales 2024
4.02x
EV / Sales 2025 3.67x
Free-Float
99.94%
Yield 2024 *
-
Yield 2025 -
1 day+0.03%
1 month+0.13%
3 months+8.81%
6 months+25.66%
Current year+34.92%
1 month 31.45
Extreme 31.45
31.5
Current year 22.13
Extreme 22.13
32.56
1 year 19.05
Extreme 19.05
32.56
3 years 11.55
Extreme 11.55
32.56
5 years 4.81
Extreme 4.81
32.56
10 years 0.73
Extreme 0.73
32.56
Manager TitleAgeSince
Chief Executive Officer 65 01/01/2024
Director of Finance/CFO 55 01/01/2024
Chief Tech/Sci/R&D Officer 62 01/06/2025
Director TitleAgeSince
Director/Board Member 48 15/07/2026
Director/Board Member - 15/07/2026
Director/Board Member - 15/07/2026
Date Insider Type Main position Quantity % Market Cap.
15/7/26 Issuer sale

Director

-63,583 0.0519%
15/7/26 Issuer sale

Director

-130,857 0.1069%
15/7/26 Issuer sale

Executive/Senior Manager

-1,051,183 0.8587%
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%-.--%+44.91%+126.22% 3.85B
+1.04%+10.56%+34.48%+0.28% 75.96B
+2.64%-8.39%+24.13%+188.08% 49.03B
+1.02%-3.74%-7.47%+21.83% 47.88B
+1.42%+9.32%-50.68%-50.72% 43.39B
-0.87%+0.50%+56.30%-23.16% 30.8B
-0.66%-7.80%+53.51%+88.28% 24.45B
-1.29%+0.81%+103.53%-48.00% 22.75B
+4.15%+0.44%-2.80%+175.30% 19.24B
-0.10%-4.16%+71.71%+162.37% 16.04B
Average +1.11%-0.72%+32.76%+64.05% 33.34B
Weighted average by Cap. +1.23%+0.58%+23.73%+44.71%

Financials

2024 2025
Net sales 492M 426M 397M 365M 689M 46.77B 697M 4.66B 1.83B 23.38B 1.85B 1.81B 77.52B 589M 510M 475M 437M 825M 56.02B 834M 5.59B 2.19B 28.01B 2.21B 2.16B 92.86B
Net income 164M 142M 132M 122M 230M 15.59B 232M 1.55B 609M 7.79B 615M 602M 25.84B 214M 185M 173M 159M 300M 20.38B 304M 2.03B 796M 10.19B 805M 787M 33.79B
Net Debt -514M -445M -415M -382M -721M -48.92B -729M -4.88B -1.91B -24.46B -1.93B -1.89B -81.09B -706M -611M -570M -525M -990M -67.18B -1B -6.7B -2.63B -33.59B -2.65B -2.59B -111B
Logo Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Employees
182
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. CPRX Stock